Feel our pain
1 October 2004

The withdrawal of the US group s arthritis drug will cause knockon effects throughout the drug sector. Merck will promote its remaining drugs heavily. Novartis and Glaxo will find life tougher. But ScheringPlough could be a beneficiary.